← All trials
NCT03192020
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 14, 2017
- Primary completion
- Dec 31, 2020
- Completion date
- Dec 31, 2020
- First posted
- —
- Last posted
- —
- Enrollment
- 278
- Arms / groups
- 3 / —
- Source
- AACT · pre-existing
Sponsors
- University of TampereLead sponsor
- Medcare LtdCollaborator
- Government of FinlandOverall official - principal investigator
- Medcare LtdOverall official - principal investigator
- University of HelsinkiOverall official - principal investigator
- University of TurkuCollaborator
- Government of FinlandCollaborator
- University of OsloCollaborator
- University of HelsinkiCollaborator
- University of TampereReponsible party - principal investigator
- Kuopio University HospitalCollaborator
- University of TampereOverall official - principal investigator
- University of TampereCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.